Introduction
Donor-specific alloantibodies (DSAs) against HLA class I and class II are a major problem in organ transplantation. DSA can cause acute and chronic rejection and can be a major barrier to finding an acceptable donor when present pretransplantation in "sensitized patients" (1) (2) (3) (4) (5) . Unfortunately, no effective therapy exists to either deplete DSAs or block their effect (6) .
While DSAs may be produced by short-lived plasmablasts and/or stimulated memory B cells, our prior studies suggest that bone marrow (BM)-derived longlived plasma cells (LLPCs) are a major source of persistent serum DSAs. LLPCs are rare (<0.5% of BM and almost nonexistent in peripheral blood), poorly characterized, and resistant to most current therapy in vivo (7) . The mechanism of resistance to therapy may be due to the fact that LLPCs reside in prosurvival microenvironments or niches in which supporting stromal cells and leukocytes provide factors that enhance LLPC longevity and prevent erstwhile apoptotic signals.
One possible receptor-ligand interaction that is important in these microenvironments is the chemokine receptor type 4 (CXCR4) and chemokine ligand 12 (CXCL12) (8) . CXCR4 (also known as fusin or CD184) is an achemokine receptor expressed on normal PCs as well as other lymphocytes and hematopoietic stem cells (9) . CXCL12 (also known as stromal derived factor 1) is a small chemokine produced by the splenic red pulp and BM stromal cells that is chemotactic for lymphocytes (10) . CXCR4 appears important in PC homing and conditional depletion of CXCR4 in mice reduces the PC numbers in the BM. Immunohistochemistry of mouse BM sections suggests that almost all IgG + CD138 + PCs are in contact with CXCL12/SDF1 + cells (11) . CXCL12/SDF1 induces interleukin-6, promoting myeloma cell growth; protects myeloma cell drug-induced apoptosis; and upregulates very late antigen 4 adhesion to fibronectin and vascular cell adhesion molecule 1 (12, 13) .
While several studies have examined the effect of CXCR4/CXCL12 interactions on PCs in vitro, there are no studies that have examined the impact of blocking these in vivo. Plerixafor (Mozobil TM ) is a macrocyclic compound that inhibits CXCR4/CXCL12 interactions and is approved by the US Food and Drug Administration to enhance mobilization of hematopoietic stem cells for transplantation in patients with lymphoma and multiple myeloma. Several studies have demonstrated that in vivo treatment with plerixafor causes the mobilization of other cell types including B and T cells as well as malignant plasma cells (PCs) in immunocompromised mice (14) (15) (16) . The impact of plerixafor on normal PCs in healthy individuals in vivo is unknown. The proteasome inhibitor bortezomib has been shown to cause apoptosis of PCs in vitro and depletion of PCs in vivo (17) . This study was therefore designed with the goals of evaluating the impact of plerixafor on normal PC homeostasis in vivo and determining if the addition of bortezomib would enhance any effects that are seen.
Methods
Mice and treatment protocols B6 mice were obtained from Jackson Laboratories (Bar Harbor, ME) and maintained under pathogen-free conditions. At the time of treatment and/ or immunization, mice were 6 to 14 weeks of age. For single-dose treatment, plerixafor (240 lg/kg to 5 mg/kg) or saline (0.1 mL) was given via intraperitoneal injection. Mice were killed either 1, 2, or 24 h after the final dose. For multidose monotherapy treatment, mice were given 1 mg/ kg plerixafor or saline daily for 10 days and then killed 1 h after the final dose. Mice given combination therapy were treated with 1 mg/kg plerixafor and then bortezomib (0.02 mg/m 2 ) 1 h later for up to 10 days. Twenty-four hours after treatment with bortezomib, the mice were killed. Studies were performed with approval of the Mayo Clinic Institutional Animal Care and Use Committee.
Splenectomies
Mice were anesthetized with an intraperitoneal injection of pentobarbital at 85 mg/kg and were given 0.1 mg/kg buprenorphine. A small left subcostal incision (10 to 15 mm) was made, and spleens were identified and carefully removed. Splenic arteries and venous supply were ligated with 4-0 Vicryl sutures. The abdominal wall was closed with 4-0 Vicryl running sutures. Mice were then treated with 1 mg/kg plerixafor and killed 1 h after treatment.
Quantification of PCs
After the mice were killed, peripheral blood was obtained through cardiac puncture. For BM isolation, the four long bones of the hind legs were dissected. The ends of the bones were removed and the BM was flushed by using a 25-gauge needle. Single-cell suspensions from BM, spleen, and peripheral blood were filtered through a 70-µm strainer (BD Falcon, Bedford, MA), washed, and resuspended in RPMI 1640 medium (Life Technologies, Carlsbad, CA). The total number of leukocytes was counted by using an AcT10 Hematology Analyzer (Beckman Coulter, Brea, CA). Cell suspensions from each tissue were stained with CD3-FITC and CD138-PEVio770 (Miltenyi Biotech, Bergisch Gladbach, Germany) for isolation via sorting flow cytometry on an FACSAria instrument (BD Biosciences, Franklin Lakes, NJ). For additional phenotype analysis, cells were also stained for CXCR3-PE, CXCR4-APC, CXCR5-PEVio610 (Miltenyi Biotech), and CXCR7-biotin (Biolegend, San Diego, CA) followed by streptavidin-PerCP (Miltenyi) and analyzed with FlowJo software (Flow Jo LLC, Ashland, OR).
Statistical methods
Analyses was made with JMPv9 (SAS, Cary, NC) using t-tests, paired or unpaired, according to the data compared as well as Wilcoxon ranked test where the sample size was less than 10. The data are represented in box plots demonstrating the interquartile ranges as well as the mean, maximum, and minimum values obtained. Unless otherwise indicated, numerical data are described by means, and nominal data are described by counts and percentages. A p-value of 0.05 or less was considered significant.
Results

Phenotypic analysis of PCs
The gating strategy for FACS isolation selected cells with high forward scatter and excluded cellular debris and dead cells ( Figure S1 ). Cells that were CD3
-and CD138 + were collected and counted. Portions of the PC isolates were saved for cytospin and hematoxylin and eosin staining to assess purity on bright field microscopy. Isolates were between 96% and 98% pure. These data also show that a small subset of CD138 + cells are CD3 + , but the vast majority are typical PCs by cell surface markers and morphologically. Pertinent to the subsequent studies using plerixafor, CXCR4 expression was high and pervasive on PCs from all compartments.
CXCR4/SDF-1 blockade mobilizes PCs into peripheral blood Becausee normal PCs express CXCR4, we hypothesized that treatment with the CXCR4 blocker plerixafor might cause mobilization of normal PCs into the peripheral blood similar to its known effect on hematopoietic stem cells.
Plerixafor at 240 lg/kg showed no increase in mobilization compared with the control group. The dose was then increased to 1 mg/kg. This dose increased the numbers of PCs in peripheral blood 1 h after administration compared with saline-treated controls (p = 0.007) ( Figure 1 , Figure S2 ). The number of PCs in the peripheral blood decreased by 2 h and returned to baseline by 24 h (not shown).
The next group of experiments was aimed to determine if further increasing the dose would augment PC mobilization. Thus, the dose escalation went from a lower dose (1 mg/kg) to a higher dose (5 mg/kg). The 5-mg dose showed significantly more mobilization compared with control but showed mobilization similar to 1 mg/kg at 1 h (Figure 1 ).
We then used a multidose regimen of plerixafor (1 mg/kg in 10 daily doses) and saline injection to controls, with the final assessment 1 h after the last (10th) injection. After 10 daily treatments, PCs continued to be mobilized into the peripheral blood in numbers that were greater than control; however, there was no difference compared with the 1-mg single dose. Therefore, we used the 1-mg/kg single dose for subsequent experiments (Figure 1 ).
Numerically, we estimate that approximately 500 000 PCs are mobilized into the peripheral blood with any one dose of plerixafor, and this is only a small portion of the millions of PCs that are present in any one compartment. PCs mobilized to the peripherial blood are positive for CXCR3, CXCR4, CXCR5, and CXCR7. The phenotype of PCs mobilized by CXCR4 blockade showed no difference compared with those circulating ( Figure S3 ).
PCs mobilized by plerixafor are primarily from the spleen PCs mobilized into the peripheral blood may originate from the BM, spleen, gastrointestinal tract, and/or lymph node. To assess if the mobilized PCs were predominantly from the spleen, splenectomy was performed 1 h before plerixafor administration (1 mg/kg) and numbers of PCs in peripheral blood assessed 1 h after treatment. Figure 2 shows that splenectomized mice failed to show an increase in peripheral blood PCs when treated with plerixafor 1 mg/kg both at 1 h and after a 10-day course of treatment and therefore suggests that most of the mobilized PCs were from the spleen ( Figure S4 ).
Impact of plerixafor on PC numbers in the spleen and BM In addition to mobilizing PCs into the peripheral blood, blockade of CXCR4/CXCL12 interactions could also have local effects on PC homeostasis in the spleen and BM. As demonstrated in Figure 3 , there was no change in the number of PCs that were present in the BM and spleen after a 10-day course of plerixafor. The phenotype of PCs in the spleen and BM of mice treated with plerixafor showed similar levels of CXCR3, CXCR4, CXCR5, and CXCR7 expression as those that did not receive plerixafor treatment, suggesting that these molecules alone are not responsible for PC retention and longevity.
Plerixafor does not enhance PC depletion by bortezomib
We hypothesized that blocking CXCR4/CXCL12 interactions with plerixafor might enhance the effect of bortezomib in vivo. Mice were treated with either bortezomib alone (0.02 mg/m 2 ) or a combination of plerixafor (240 lg/kg to 1 mg/kg) and bortezomib (0.02 mg/m 2 ). Mice were first injected with plerixafor and then bortezomib 1 h later (i.e. at the time of maximum mobilization for PCs) for up to 10 days. Mice were killed 24 h after the final treatment with bortezomib. Combination therapy with bortezomib plus plerixafor, at all doses tested, did not lead to a decrease in PC numbers in the spleen or BM, even with multiple cycles of treatment (Figure 4 ).
Discussion
Deciding on approaches to alloantibody depletion is hampered by the lack of detailed studies of PCs. Studies in other areas such as multiple myeloma have commonly used combination therapies to deplete PC to enhance efficacy and decrease toxicity (18) . The CXCR4/CXCL12 interaction has been shown to be preserved throughout the animal kingdom (19) . Plerixafor blocks the CXCR4 receptor and therefore mobilizes malignant PC into the peripheral blood in patients with non-Hodgkin's lymphoma and multiple myeloma (20) . This study was conducted to further investigate this effect in normal PCs and to look at whether combining this drug with bortezomib would lead to an enhanced reduction of PCs, which could be of therapeutic benefit in the transplant population.
The overall results showed that there was an increase in PC mobilization that was reflected in the increased number of PCs in the peripheral blood after treatment; however, there was no reduction in PC numbers in the spleen and BM after treatment. There was also no enhancement of PC depletion when bortezomib was added in combination with plerixafor.
These results suggest that most PCs in the spleen and BM do not depend solely on CXCR4/CXCL12 interactions for retention and longevity. Thus, our findings are consistent with those of Hauser et al showing IgG antibody secreting cells (ASCs) appear to lose responsiveness toward CXCL12/SDF1 within 6 days after arrival in the BM (21) . In that study, CXCR4 expression appeared unchanged despite decreased dependence on CXCL12. In our current study, CXCR4 expression on PCs was similar in the BM, spleen, and peripheral blood, yet blocking CXCR4/CXCL12 interactions did not lead to significant mobilization of PCs from the BM or an increase in depletion when combined with bortezomib. The specific characteristics of these mobilized splenic PCs are unclear. We estimate that a single dose of plerixafor mobilizes only 500 000 splenic PCs of the millions that are present.
One possibility for the findings is that plerixafor leads to depletion of some PCs with rapid replacement by new ones; however, an impact on proliferation cannot be ruled out. Additional phenotype analysis of the mobilized PCs and the PCs remaining in the BM and spleen beyond CXCR3, CXCR4, CXCR5, and CXCR7 would assist in elucidating the differences in these cell populations. While some data suggest that PC longevity may be partially due to intrinsic differences between PCs (e.g. increased expression of Blimp-1, increased ability to handle highvolume antibody production via increased proteasome activity, or increased X-box protein expression) (22) , other studies suggest an extrinsic control of PC longevity ) led to an enhanced depletion of PCs from the spleen compared with control; however, when a combination of plerixafor 1 mg/kg and bortezomib 0.02 mg/m 2 was administered, after 24 h, the number of PCs remaining in the spleen was no different from those for controls (p > 0.14) or bortezomib alone (p > 0.45) or plerixafor alone (p > 0.44). The same was true when a 10-day course of plerixafor 1 mg/kg and bortezomib was administered. (B) The findings were similar in the bone marrow; the number of PCs isolated from the bone marrow of the combination drug treatment mice given single-dose and 10-day treatment course was no different from the controls, bortezomib only, and plerixafor (1 mg/kg) only treatment groups.
(primarily based on the ability of stromal cells to support PC longevity in vitro and decreased numbers of long-lived PCs when interleukin-6 is knocked out in mice) (10, 23) . Stromal cell lines and long-term cultured nonlymphoid cells from either the BM or secondary lymphoid tissue have been shown to increase PC survival in vitro and to increase antibody production. Microenvironments appear to vary among different lymphoid compartments. For example, in the spleen, dendritic cells and basophils have been shown to support PC survival, while the BM used eosinophils and megakaryocytes. The current study does not specifically address the issue of intrinsic versus extrinsic causes of PC longevity, but it does show that CXCR4/ CXCL12 interactions appear to be important for longevity in only a small subset of PCs and that the effect may depend not only on the type and site of the microenvironment but also on specific factors of the PC.
The results here have implications for the clinical use of plerixafor. Becausee several diseases and conditions are due to antibodies, therapy that depletes normal PCs is needed. Plerixafor, either alone or in combination with bortezomib, could be a potentially useful approach to depleting PCs, attacking its microenvironment and, thus, making PCs more sensitive to the proapoptotic effects of proteasome inhibition. The current study, while limited in scope and carrying all the limitations of extrapolating a mouse model to humans, suggests that blocking CXCR4/ CXCL12 interactions is unlikely to be effective adjunct therapy, at least at the doses measured. On the other hand, the findings that normal PCs in the BM are relatively unaffected by plerixafor are encouraging and suggest that decreased antibody secretion is unlikely to be a side effect of plerixafor-a fortunate finding in that it may be given for the mobilization of hematopoietic stem cells in healthy donors and for autologous transplants, two situations in which the preservation of normal antibody production is paramount.
We conclude that CXCR4/CXCL12 interactions are important to the localization and longevity of a subset of splenic PCs. However, the majority of PCs are unaffected, suggesting that factors other than CXCR4/CXCL12 are important for PC retention and the longevity of most normal PCs in the spleen and BM.
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Additional Supporting Information may be found in the online version of this article. + CD3 -PCs in the peripheral blood at 1 h. The numbers returned to baseline levels after 24 h. Figure S3 : Cells from the spleen, bone marrow, and peripheral blood express similar levels of chemokine receptors 3, 4, 5, and 7 both with and without CXCR4 blockade. Cells from the peripheral blood, bone marrow, and spleen were isolated from mice sacrificed one hour after treatment with 1 mg/kg plerixafor (grey) and compared to control treated with PBS (black). The cells were then stained for the chemokine receptor markers CXCR3, CXCR4, CXCR5, and CXCR7. Each compartment showed similar levels of chemokine receptor expression with or without treatment. Figure S4 : Splenectomy abrogates mobilization of PCs to the peripheral blood. Mice treated with plerixafor (1 mg/kg) after splenectomy showed similar levels of peripheral blood PCs compared to controls, whereas mice treated with plerixafor that did not undergo splenectomy showed increased levels of PCs in the peripheral blood (left panels). Levels of PCs in the bone marrow remained consistent with and without plerixafor treatment and/or splenectomy, suggesting a majority of mobilized PCs come from the spleen.
